Phase I–II trial of mitoxantrone in acute leukemia: an interim report

Zalmen A. Arlin(Leukemia and Lymphoma Society), Gary Dukart, Ingrid Schoch, A Reisman(American Medical Research), Richard A. Gams(Breast Center), Joseph O. Moore(Cancer Institute (WIA)), Richard A. Silver(NewYork–Presbyterian Hospital), Joseph Bertino(Yale University), Peter A. Cassileth(City Of Hope National Medical Center)
Investigational New Drugs
June 1, 1985
10.1007/bf00174173
Cited by 22

Related Papers

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
|Journal of Clinical Oncology|1990|785
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
|Journal of Clinical Oncology|1997|652
A common progenitor for human myeloid and lymphoid cells
|Nature|1978|277